伊伐布雷定成功治疗一名射血分数降低的急性失代偿性心力衰竭且对β受体阻滞剂难治的患者。
Successful treatment with ivabradine in a β-blocker-refractory patient with acute decompensated heart failure with reduced ejection fraction.
作者信息
Inoue Tomoko, Matsunaga Keiji, Kobayashi Waki, Minamino Tetsuo
机构信息
Department of Cardiorenal and Cerebrovascular Medicine Faculty of Medicine Kagawa University Kagawa Japan.
出版信息
Clin Case Rep. 2023 Mar 4;11(3):e6890. doi: 10.1002/ccr3.6890. eCollection 2023 Mar.
Abstract
Ivabradine is an established treatment for chronic heart failure with reduced ejection fraction (HFrEF); however, it is not used for acute heart failure treatment. Negative inotropic effects (NIE) often limit the up-titration of β-blockers. Contrarily, ivabradine has no NIE, and enables β-blockers usage for treating patients with acute decompensated HFrEF.
摘要
伊伐布雷定是一种已被认可的用于治疗射血分数降低的慢性心力衰竭（HFrEF）的药物；然而，它并不用于急性心力衰竭的治疗。负性肌力作用（NIE）常常限制β受体阻滞剂的剂量上调。相反，伊伐布雷定没有负性肌力作用，并且能够使β受体阻滞剂用于治疗急性失代偿性HFrEF患者。
Zotero 插件